AMF | Jotup

Changes to Ericsson's nomination committee

Retrieved on:

Jeudi, novembre 30, 2023

STOCKHOLM, Nov. 30, 2023 /PRNewswire/ -- Effective November 30, 2023, Bengt Kjell, AB Industrivärden, will replace Karl Åberg, AB Industrivärden, in Ericsson's (NASDAQ: ERIC) Nomination Committee.

Key Points:

STOCKHOLM, Nov. 30, 2023 /PRNewswire/ -- Effective November 30, 2023, Bengt Kjell, AB Industrivärden, will replace Karl Åberg, AB Industrivärden, in Ericsson's (NASDAQ: ERIC) Nomination Committee.
The Nomination Committee now consists of:
Anders Oscarsson, AMF Tjänstepension & AMF Fonder;
Jan Carlson, the Chair of the Board of Directors.
Johan Forssell is the Chair of the Nomination Committee.

Changes to Ericsson's nomination committee

Retrieved on:

Jeudi, novembre 30, 2023

AMF, AB, Committee, Ericsson

STOCKHOLM, Nov. 30, 2023 /PRNewswire/ -- Effective November 30, 2023, Bengt Kjell, AB Industrivärden, will replace Karl Åberg, AB Industrivärden, in Ericsson's (NASDAQ: ERIC) Nomination Committee.

Key Points:

STOCKHOLM, Nov. 30, 2023 /PRNewswire/ -- Effective November 30, 2023, Bengt Kjell, AB Industrivärden, will replace Karl Åberg, AB Industrivärden, in Ericsson's (NASDAQ: ERIC) Nomination Committee.
The Nomination Committee now consists of:
Anders Oscarsson, AMF Tjänstepension & AMF Fonder;
Jan Carlson, the Chair of the Board of Directors.
Johan Forssell is the Chair of the Nomination Committee.

NANOBIOTIX Announces Closing of Global Offering

Retrieved on:

Mardi, novembre 7, 2023

PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares (the “Underwriters’ Option”) in the form of American Depositary Shares (“ADSs”).

Key Points:

PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares (the “Underwriters’ Option”) in the form of American Depositary Shares (“ADSs”).
The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
Jefferies LLC, Leerink Partners and Guggenheim Securities acted as global coordinators and joint bookrunners for the Global Offering.
The Global Offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

Bonduelle - First Quarter FY 2023-2024 Revenue: Business growth in line with annual target

Retrieved on:

Mardi, novembre 7, 2023

Bonduelle, Weather, Pressure, Acquisition, Environment, Growth, Rue Nicolas-Appert, Annual, Depreciation, AMF, Retail, Food preservation, Cryptocurrency, Life insurance, Holding company, Mercosur, 1964 Davis Cup Europe Zone

Despite this environment, the food service activity remains flat overall in terms of volumes but is growing in value.

Key Points:

Despite this environment, the food service activity remains flat overall in terms of volumes but is growing in value.
The Bonduelle Group announces that its 2022-2023 Universal Registration Document was filed with the Autorité des marchés financiers (AMF) on October 19, 2023.
The revenues in foreign currency over the given period are translated into the rate of exchange for the comparable period.
Alternative performance indicators: the group presents in its financial notices performance indicators not defined by accounting standards.

Keysight Announces the Filing of a Tender Offer for all Remaining Outstanding Shares of ESI Group at a Price of 155 Euros Per Share

Retrieved on:

Mardi, novembre 7, 2023

Keysight Technologies, Inc. (NYSE: KEYS), which currently owns 50.6% of the share capital and 46.3% of the theoretical voting rights of ESI Group SA (Euronext Paris Symbol: ESI) (“ESI Group”), today announces the filing of the tender offer for all remaining outstanding shares of ESI Group.

Key Points:

Keysight Technologies, Inc. (NYSE: KEYS), which currently owns 50.6% of the share capital and 46.3% of the theoretical voting rights of ESI Group SA (Euronext Paris Symbol: ESI) (“ESI Group”), today announces the filing of the tender offer for all remaining outstanding shares of ESI Group.
J.P. Morgan SE and BNP Paribas are acting as presenting banks on the Offer, with BNP Paribas acting as guaranteeing bank.
The tender offer, as well as the draft offer document, will remain subject to review by the AMF, which will assess their conformity with the relevant legal and regulatory provisions.
Based on this, the Board unanimously concluded that, in its reasoned opinion, the Offer was in the best interests of ESI Group, its shareholders and its employees.

After 2 years of optimizing its online databases, Artmarket.com posts substantial Q3 2023 turnover growth: up 75%

Retrieved on:

Mardi, novembre 7, 2023

As a result, our turnover for the 3rd quarter of 2023 has posted a 75% increase versus the year-earlier period.

Key Points:

As a result, our turnover for the 3rd quarter of 2023 has posted a 75% increase versus the year-earlier period.
From early September 2023, the final online version of Artprice.com by Artmarket , World Leader in Art Market Information for 25 years, has become the Art Market benchmark in terms of customer experience and ergonomics.
In the long term, we can therefore expect significant turnover growth (due to higher traffic) and this has already been confirmed by our Q3 2023 figures which show a 75% turnover increase vs. Q3 2022.
With the new advertising revenue, Artprice by Artmarket expects to double its turnover in 2023/2024 versus the previous financial year.

After 2 years of optimizing its online databases, Artmarket.com posts substantial Q3 2023 turnover growth: up 75%

Retrieved on:

Mardi, novembre 7, 2023

As a result, our turnover for the 3rd quarter of 2023 has posted a 75% increase versus the year-earlier period.

Key Points:

As a result, our turnover for the 3rd quarter of 2023 has posted a 75% increase versus the year-earlier period.
From early September 2023, the final online version of Artprice.com by Artmarket , World Leader in Art Market Information for 25 years, has become the Art Market benchmark in terms of customer experience and ergonomics.
In the long term, we can therefore expect significant turnover growth (due to higher traffic) and this has already been confirmed by our Q3 2023 figures which show a 75% turnover increase vs. Q3 2022.
With the new advertising revenue, Artprice by Artmarket expects to double its turnover in 2023/2024 versus the previous financial year.

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

Retrieved on:

Lundi, novembre 6, 2023

Exercise, NANO, Prospectus, Nanobiotix, Cancer, Patient, AMF, Medical device, Euronext

million as well as the partial exercise of the over-allotment option granted to the underwriters by the Company for an additional amount of approximately $3.6M.

Key Points:

million as well as the partial exercise of the over-allotment option granted to the underwriters by the Company for an additional amount of approximately $3.6M.
The first share capital increase has been subscribed by qualified investors for an aggregate gross amount of approximately $30 million.
This capital increase has been increased by an additional amount of approximately $3.6 million following the partial exercise of the over-allotment option.
The second share capital increase has been subscribed by Johnson & Johnson Innovation - JJDC, Inc. (“JJDC”) for an aggregate gross amount of approximately $20.2 million.

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Retrieved on:

Jeudi, novembre 2, 2023

The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.

Key Points:

The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
Jefferies LLC, Leerink Partners and Guggenheim are acting as global coordinators and joint bookrunners for the Global Offering.
The Global Offering is subject to an underwriting agreement, which was entered into on November 2, 2023.
The expected use of proceeds represents the Company’s intentions based upon its current plans and business conditions.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on:

Mercredi, novembre 1, 2023

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points:

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.